Roger Ulrich, PhD
Dr. Roger Ulrich is an entrepreneur and biotech executive with more than 30 years of operational and administrative experience in the pharmaceutical industry. In addition to serving on the Board of Directors for Aminex, he is a member of the Board for Acerta Pharma BV, and served as the company’s Chief Scientific Officer until the majority acquisition by AstraZeneca in 2016. He is also on the Board for Remedy Pharmaceuticals, is a Senior Advisor to Frazier Healthcare Partners, and serves as a scientific advisor to several start-up companies. Prior to Acerta, he was Founder and Chief Development Officer at Calistoga Pharmaceuticals Inc., acquired by Gilead in 2011, where he led the development of CAL-101 (GS-1101, idelalisib) now approved as Zydelig® for the treatment of patients with hematologic malignancies. Prior to Calistoga, Dr. Ulrich was Senior Scientific Director with Merck Research Laboratories/Rosetta Inpharmatics, Director of Regulatory Toxicology, Safety Pharmacology, Genetic Toxicology, Cellular and Molecular Toxicology, Microscopy and Microanalysis at Abbott Laboratories, and a Senior Scientist with The Upjohn Company and Pharmacia & Upjohn Inc. Prior to his pharmaceutical industry career he held positions at Michigan State and West Virginia Universities, and at Argonne National Laboratories. Dr. Ulrich holds several patents and has authored more than 120 publications. He received his Bachelor of Arts degree in Biology/Chemistry and his Masters of Arts in Biomedical Sciences from Western Michigan University. He received his doctorate in Cellular and Molecular Biology from West Virginia University, and is a Fellow of the Academy of Toxicological Sciences.